Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

Stanford University

Status: Completed

Conditions: Diabetic Macular Edema

Treatments: Drug: Intravitreal Injection of Aflibercept

Study type: Observational

Funder types: Other

Identifiers

NCT02000102

28279

Details and patient eligibility

About

Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.

Enrollment: 14 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab -

Exclusion Criteria: None

Trial design

14 participants in 1 patient group

Diabetic Macular Edema Patients Switched to Aflibercept

Treatment:

Drug: Intravitreal Injection of Aflibercept